Publication|Articles|February 11, 2025

Supplements and Featured Publications

  • Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis

Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis

Listen
0:00 / 0:00

This Clinical Brief is supported by Boehringer Ingelheim.

This article provides an overview of generalized pustular psoriasis (GPP) and its clinical and economic impact, and reviews findings of Effisayil® 2, the first trial to study subcutaneous Spevigo® (spesolimab-sbzo) in patients with GPP when not experiencing a flare.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo